You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Direct-read monitor for airborne viral pathogens

    SBC: AEROSOL DEVICES INC            Topic: NIAID

    Aerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. MegaTrans- human transporter machine learning models

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: 400

    Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effectsOATP BSLCO Band OATP BSLCO Bare `uptakeandapostransporters largely restricted to the sinusoidal aspect of hepatocytesThey both transport a wide variety of structurally unrelated compoundsincluding members of s ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Development of a Highly Specific Dengue Diagnostic Test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Medications for Synthetic Cannabinoid Abuse

    SBC: PAFOSPharma, LLC            Topic: R41

    PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: ENGINEERING RESOURCES GROUP INC            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Automated CRISPR Screening Using the CellRaft Technology

    SBC: CELL MICROSYSTEMS INC            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government